CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.

Ning PuGuochao ZhaoHanlin YinJian-Ang LiAbulimiti NuerxiatiDansong WangXuefeng XuTiantao KuangDayong JinWenhui LouWenchuan Wu

Published in: Journal of translational medicine (2018)

The combination of CD25, TGF-β and PD-1 blockade plays a potentially effective role in inhibiting tumor formation and progression. Our results also provide a strong rational strategy for use of IIR in future immunotherapy clinical trials.

Keyphrases

clinical trial
transforming growth factor
signaling pathway
nk cells
current status
epithelial mesenchymal transition
randomized controlled trial
study protocol
placebo controlled